PROJECT: RESPONSIBLE ANTIBIOTICS MANUFACTURING PLATFORM (RAMP)About RAMP

The Responsible Antibiotics Manufacturing Platform, RAMP, seeks to set a new standard for the industry. Through the platform, procurers, regulators, and companies co-create the business case for responsible production of antibiotics.

Mission 

To lead industry transformation towards responsible antibiotics manufacturing to reduce the spread of antimicrobial resistance.

Vision 

A global antibiotic manufacturing industry leading the fight against antimicrobial resistance.

The platform was first presented in India, a major manufacturing hub determined to reduce AMR-driving emissions from its production facilities. Since then, RAMP has attracted the interest of European countries that import antibiotics.

 

Since 2021
Global

What makes RAMP unique

RAMP is a partnership between pioneers in the antibiotics industry and other stakeholders. The partnership engages members across the supply chain to demonstrate sustainable yet low-cost solutions. RAMP leverages change by defining verifiable, demand-driven and scientifically sound criteria for responsible antibiotic manufacturing.

Learn about How RAMP works

THE RAMP PARTNERSHIP IS MADE IN COLLABORATION WITH
Shawview Consulting
Shawview Consulting
swiss_logo
Swiss Agency for Development and Cooperation (SDC)
Centrient Pharmaceuticals
Centrient Pharmaceuticals
GlaxoSmithKline
GlaxoSmithKline (GSK)
Novartis
Novartis
sandoz-vector-logo
Sandoz
AMR Industry logo with coloured bubbles
AMR Industry Alliance (Technical partner)
Default Image

Join RAMP

For exchange of information, expertise and ability to co-create verifiable criteria for responsible antibiotic manufacturing in a trusted and mutually supportive platform.

See how you can engage

Background

The World Health Organization has warned that antimicrobial resistance (AMR) could claim 10 million lives per year by 2050 and jeopardise many of the health gains made in the past century. In 2022, a Lancet report confirmed that ‘AMR is a leading cause of death around the world, with the highest burdens in low-resource settings’.

In May 2022, global leaders issued an urgent call for all countries to reduce antimicrobial pollution. This includes the safe disposal of antimicrobial waste from manufacturing facilities. Effluent from antibiotic manufacturing causes severe environmental pollution through residue in water and river systems contributing to AMR.

RAMP was launched in 2020, building on SIWI’s past work with pharmaceutical industries to reduce the spread of AMR. The platform was first presented in India, a major manufacturing hub determined to reduce AMR-driving emissions from its production facilities. Since then, RAMP has attracted the interest of European countries that import antibiotics.